One of the most common assumptions in healthcare innovation is that the best product will win.
It’s an understandable belief. If a product delivers better outcomes, improves efficiency or solves an important problem, success should naturally follow.
In reality, healthcare markets rarely work that way.
Over the years I’ve seen products with genuine clinical value struggle to gain traction, while other solutions achieved strong adoption despite appearing less impressive on paper.
The difference is often not the product itself.
The difference is understanding how healthcare organisations make decisions and what it takes for change to occur.
Healthcare professionals care deeply about outcomes.
Clinical evidence matters. Product performance matters. Patient impact matters.
However, these factors are only part of a much larger decision-making process.
A healthcare organisation may agree that a product is beneficial while still deciding not to adopt it.
Why?
Because the product also needs to fit within operational, financial and organisational realities.
Questions such as:
often become just as important as clinical performance.
In many industries, purchasing decisions can be made quickly by a single decision maker.
Healthcare rarely works that way.
A clinician may identify a need.
A department manager may support the proposal.
Procurement may evaluate suppliers.
Finance may review budgets.
Executives may assess strategic priorities.
Each stakeholder views the opportunity through a different lens.
A product that resonates strongly with one group may raise concerns for another.
Successful healthcare commercialisation requires understanding these perspectives from the beginning rather than treating them as obstacles that appear later.
One issue that is consistently underestimated is workflow impact.
Many healthcare products are designed to improve outcomes. Far fewer are designed around how care is actually delivered.
A product may be clinically effective but still struggle because implementation creates friction.
Even small workflow changes can affect:
The reality is that healthcare environments are busy, resource constrained and often under significant operational pressure.
Products that integrate naturally into existing workflows generally face fewer barriers to adoption.
When organisations think about evidence, they often focus primarily on clinical validation.
Clinical evidence is critical, but it is rarely the only evidence stakeholders require.
Decision makers may also want to understand:
Different stakeholders look for different forms of evidence.
The challenge is not generating data.
The challenge is generating the right evidence for the people involved in the decision.
Every healthcare product introduces some degree of change.
Sometimes that change is minor.
Sometimes it is significant.
Either way, adoption ultimately requires individuals and organisations to do something differently than they do today.
This is where many commercialisation strategies fall short.
The product is ready.
The evidence is available.
The launch plan exists.
Yet insufficient attention has been given to helping people navigate the change itself.
Adoption is rarely a single event. It is a process.
Understanding that process can have an enormous impact on commercial outcomes.
One pattern I’ve observed repeatedly is organisations delaying commercial discussions until product development is largely complete.
At that point, many important decisions have already been made.
The strongest healthcare innovations often begin with commercial questions alongside technical and clinical questions.
Who will benefit?
Who will influence adoption?
What barriers are likely to emerge?
What evidence will be required?
How will success be measured?
Thinking about these issues early rarely slows development. More often, it helps focus development efforts on what matters most.
Healthcare innovation is essential.
New technologies and new approaches continue to improve outcomes for patients and providers alike.
However, innovation and adoption are not the same thing.
The products that succeed commercially are often those that combine strong clinical value with stakeholder understanding, practical implementation and thoughtful commercial planning.
Some of the most impressive healthcare products never achieve the adoption their creators expected.
Not because they lack value.
Not because they fail clinically.
But because adoption depends on much more than the product itself.
Healthcare product success sits at the intersection of clinical outcomes, operational realities, stakeholder priorities and commercial strategy.
The most important question is often not:
“Does this product work?”
It’s:
“What will it take for people to adopt it?”